Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

DARA BioSciences Inc

+ Add to Watchlist

DARA:US

0.8350 USD 0.0200 2.34%

As of 20:10:00 ET on 01/30/2015.

Snapshot for DARA BioSciences Inc (DARA)

Open: 0.8499 Day's Range: 0.8200 - 0.8500 Volume: 73,208
Previous Close: 0.8550 52wk Range: 0.7400 - 3.6500 1-Yr Rtn: -75.79%

Stock Chart for DARA

No chart data available.
  • DARA:US 0.8350
  • 1D
  • 1M
  • 1Y
0.8550
Interactive DARA Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for DARA

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.8000
Est. EPS (USD) (12/2014) -0.7000
Est. PEG Ratio -
Market Cap (M USD) 16.36
Shares Outstanding (M) 19.59
30 Day Average Volume 216,267
Price/Book (mrq) 0.9805
Price/Sale (ttm) 8.5721
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 02/04/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for DARA

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for DARA

DARA BioSciences, Inc. is a development stage pharmaceutical company. The Company acquires therapeutic molecules and medical technologies directly or through investment in established companies. DARA focuses on small molecules from late preclinical development through phase 2 clinical trials for neuropathic pain, metabolic diseases, and dermatological disorders.

David J DrutzChairman/Chief Medical OfficerChristopher G ClementPresident/CEO
David L TousleyChief Financial Officer
More Company Profile & Key Executives for DARA

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil